Pulmonary disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Informed consent or an IRB-approved informed waiver is required prior to any research-specific procedure; 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC that progressed after prior egFR-TKI therapy of any generation; 3. The patient signs an informed consent form or the EC grants an informed exemption, agreeing to provide fresh samples (tumor tissue and blood samples) or archived specimens or previous test results. Samples should be obtained after prior EGFR-TKI therapy and before the use of MET inhibitors.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MET amplification results of FISH test of tumor tissue carried out by hospital department;The RESULTS of MET amplification were detected by NGS in central laboratories and hospital departments; | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline characteristics: demographics, relevant medical history, disease characteristics, and history of cancer treatment; | — |
Countries
China
Contacts
West China Hospital, Sichuan University